1,145 results on '"Delaloge, Suzette"'
Search Results
102. INTERCEPTION : construire la prévention des cancers de demain
103. A second-generation antibody–drug conjugate to treat HER2-positive breast cancer
104. Current and Evolutionary Analysis of Early Relapsed Metastatic Triple Negative Breast Cancer in the Nationwide ESME Cohort
105. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
106. Additional file 1 of Buffy coat signatures of breast cancer risk in a prospective cohort study
107. Additional file 1 of Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
108. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
109. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
110. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
111. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer.
112. Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort.
113. Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions
114. Disease-free survival does not differ according to fertility preservation technique for young women with breast cancer
115. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer
116. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
117. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
118. PROACT: Implementing a PROACTive care pathway to empower and support breast cancer (BC) survivors.
119. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations
120. Rethinking breast cancer follow-up based on individual risk and recurrence management
121. Out-of-hospital follow-up after low risk breast cancer within a care network: 14-year results
122. First international consensus guidelines for breast cancer in young women (BCY1)
123. Chk1 as a new therapeutic target in triple-negative breast cancer
124. Exploring frontiers: Use of complementary and alternative medicine among patients with early-stage breast cancer
125. Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions
126. Decision-making from multidisciplinary team meetings to the bedside: Factors influencing the recruitment of breast cancer patients into clinical trials
127. Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety
128. Pattern of relapse in low‐risk breast cancer patients followed within a community care network
129. The role of Oncoplastic Breast Surgery in the management of breast cancer treated with primary chemotherapy
130. Factors influencing the decision to offer immediate breast reconstruction after mastectomy for ductal carcinoma in situ (DCIS): The Institut Gustave Roussy Breast Cancer Study Group experience
131. Retinoic Acid Receptor Alpha Amplifications and Retinoic Acid Sensitivity in Breast Cancers
132. Whole exome sequencing of rare aggressive breast cancer histologies
133. A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
134. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer
135. DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
136. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
137. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
138. Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS
139. Quantification of residual risk of relapse in breast cancer patients optimally treated
140. Added Value of Contrast-Enhanced Spectral Mammography in Postscreening Assessment
141. sj-docx-1-tam-10.1177_17588359221083956 ��� Supplemental material for AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2��� advanced breast cancer
142. Additional file 1 of Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the 'My Personal Breast Screening' (MyPeBS) randomised clinical trial
143. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing
144. A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort
145. MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40–70: Focus on recruitment strategy in France
146. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
147. The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions
148. Change in the value of work after breast cancer: evidence from a prospective cohort
149. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
150. Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.